MRX 6313Alternative Names: MRX-6313
Latest Information Update: 22 Jul 2016
At a glance
- Originator University of North Carolina at Chapel Hill
- Developer Meryx
- Class Small molecules
- Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Receptor protein-tyrosine kinase antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Haematological malignancies; Solid tumours